



## EXPRESS MAIL CERTIFICATE

Date \_\_\_\_\_ Label No. \_\_\_\_\_  
I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

Customer No.: 07278

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR  
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS  
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Docket No.: 03991/000K379-US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mark Andrew GUTHRIDGE; Michael Claude BERNDT; Frank Charles STOMSKI; Angel Francisco LOPEZ

Serial No.: 10,099,895

Confirmation No.: 5422

Filed: March 14, 2002

For: A BINDING MOTIF OF A RECEPTOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Patent Application  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

In order to comply with the Duty of Disclosure under 37 CFR 1.56,

Applicants submit herewith a Supplemental Information Disclosure Statement,

including Form PTO/SB/08A and copies of the documents listed thereon. It is believed that this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits and in accordance with 37 C.F.R. 1.97 (b)(4). It is therefore believed that no fee is required for this submission. However, should the U.S. Patent and Trademark Officer determine that any fee is required or that any refund is owed for this application, the Commissioner is hereby authorized and requested to charge the required fee's and/or credit the refund(s) owed to our Deposit Account No 04-0100.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08A) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO/SB/08A next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be


construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not initialed.


Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: October 6, 2003

DARBY & DARBY  
Post Office Box 5257  
New York, NY 10150-5257  
(212) 527-7700

  
Paul F. Fehlner, Ph.D.  
Registration No. 35,135  
Attorney for Applicant(s)

  
By: Samuel S. Woolley  
Reg. No. 43,287

Serial No. 10,099,895

Docket No. 3991/OK379

- 3 -



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/099,895
				Filing Date	March 14, 2002
				First Named Inventor	Mark A. Guthridge
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	03991/000K379-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	WO-92 01788-A1	02-06-1992	Schering Corp.	T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	2	DATABASE SWISSPROT 'Online! Cytokine receptor common beta chain precursor, 1 October 1993, Database accession no. p32927, XP002238516			
	3	GONDA THOMAS J ET AL: "Activating mutations in cytokine receptors: Implications for receptor function and role in disease.", BLOOD, vol. 89, no. 2, 1997, pages 355-369, XP002238511			
	4	MUSLIN A J ET AL: "Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine", CELL, CELL PRESS, Cambridge, MA, US, vol. 84, 22 March 1996, pages 889-897, XP002089347			
	5	BAGLEY C J ET AL: "The Structural And Functional Basis of Cytokine Receptor Activation: Lessons From The Comm Beta Subunit of the Granulocyte-Macrophage Colony-Stimulating Factor, Interleukins-3 (IL-3), And IL-5 Receptors", BLOOD, W.B. SAUNDERS, Philadelphia, PA, US, vol. 89, no. 5, 1 March 1997, pages 1471-1482, XP 001052641			
	6	DE GROOT ROLF P ET AL: "Regulation of Proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family", CELLULAR SIGNALLING, vol. 10, no. 9, October 1998, pages 619-628, XP002238512			
	7	JUCKER MANFRED ET AL: "Identification of a new adapter protein that may link the common beta subunit of the receptor for granulocyte/macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 to phosphatidylinositol 3-kinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 46, 1995, pages 27817-27822, XP002238513			
	8	SMITH ALISON ET AL: "Cytoplasmic domains of the common beta-chain of the GM-CSF/IL-3/IL-5 receptors that are required for inducing differentiation or clonal suppression in myeloid leukaemic cell lines", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 3, 1997, pages 451-464, XP002238514			
	9	SAKAMAKI K ET AL: "Critical Cytoplasmic Domains of the Common Beta Subunit of the Human GM-CSF, IL-3 and IL-5 Receptors For Growth Signal Transduction and Tyrosine Phosphorylation"; EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 10, 1992, pages 3541-3549, XP002070273			
	10	LIU Y-C ET AL: "Serine phosphorylation of Cbl induced by phorbol ester enhances its association with 14-3-3 proteins in T cells via a novel serine-rich 14-3-3-binding motif",			

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	03991/000K379-US0
-------	---	----	---	------------------------	-------------------

		JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 15, 11 April 1997, pages 9979-9985, XP002089346	
	11	SUN Q ET AL: "Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors", BLOOD, vol. 94, no. 6, pages 1943-1951, XP002238515	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



60-8-07 Image

1646

Application No. (if known): 10/099,895

Attorney Docket No.: 03991/000K379-US0

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

EV 982101970 US

MS Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on October 6, 2003  
Date

  
\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (3pp)  
PTO/SB/08a with 11 documents  
Return Postcard